 |
EnteroMedics to Present at Canaccord Genuity 2012 Medical Technology and Diagnostic Forum
Nov 19, 2012
|
12.4 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 11/19/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Mark B. Knudson, Ph.D., EnteroMedics' President and Chief Executive Officer, is scheduled to present at the ...
|
|
EnteroMedics to Present at the Piper Jaffray 24th Annual Healthcare Conference
Nov 15, 2012
|
11.8 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 11/15/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Mark B. Knudson, Ph.D., EnteroMedics' President and Chief Executive Officer, is scheduled to participate in ...
|
|
EnteroMedics Announces EMPOWER Trial Hypertension Data Presented at the American Heart Association's 2012 Scientific Sessions
Nov 7, 2012
|
61.8 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 11/07/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that hypertension data from a subgroup analysis of the EMPOWER trial were presented today at the American Heart A...
|
|
EnteroMedics to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
Nov 6, 2012
|
12.3 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 11/06/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Mark B. Knudson, Ph.D., EnteroMedics' President and Chief Executive Officer is scheduled to present at the ...
|
|
EnteroMedics Reports Third Quarter 2012 Financial Results
Oct 24, 2012
|
18.2 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 10/24/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced financial results for the three and nine months ended September 30, 2012.
For the three months end...
|
|
EnteroMedics to Host Third Quarter 2012 Financial Results Conference Call and Provide Business Update
Oct 17, 2012
|
12.3 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 10/17/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it will host a conference call on Wednesday, October 24, 2012 at 11:00 AM Eastern Time to discuss corporate...
|
|
EnteroMedics Secures a $45 Million Committed Issuer Managed Equity Financing Facility With Terrapin Opportunity, L.P.
Oct 4, 2012
|
12.6 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 10/04/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it has obtained a committed issuer managed equity financing facility under which it may from time to time s...
|
|
EnteroMedics to Present at Craig-Hallum 3rd Annual Alpha Select Conference
Sep 20, 2012
|
12.2 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 09/20/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Greg S. Lea, SVP and Chief Financial Officer, is scheduled to present at the Craig-Hallum 3rd Annual Alpha ...
|
|
EnteroMedics to Participate in the Lazard Capital Markets Third Annual Medical Technology 1x1 Corporate Access Day
Sep 11, 2012
|
11.5 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 09/11/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the company will participate in the Lazard Capital Markets Third Annual Medical Technology 1x1 Corporate Ac...
|
|
EnteroMedics Reports Second Quarter 2012 Financial Results
Aug 7, 2012
|
18.1 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 08/07/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced financial results for the three and six months ended June 30, 2012.
For the three months ended Jun...
|
|
EnteroMedics to Present at 32nd Annual Canaccord Genuity Growth Conference
Aug 6, 2012
|
12.2 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 08/06/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Mark B. Knudson, Ph.D., President and Chief Executive Officer, is scheduled to present at the 32nd Annual Ca...
|
|
EnteroMedics to Host Second Quarter 2012 Financial Results Conference Call and Provide Business Update
Jul 25, 2012
|
12.3 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 07/25/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it will host a conference call on Tuesday, August 7, 2012 at 11:00 AM Eastern Time to discuss corporate upda...
|
|
EnteroMedics Reports Exercise of 1,653,635 Common Stock Warrants
Jul 12, 2012
|
11.9 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 07/12/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders today announced that it has received $3.6 million from the exercise of 1,653,635 warrants through 2012 to date. The warrants that...
|
|
EnteroMedics to Present at Seventh Annual JMP Securities Healthcare Conference
Jul 9, 2012
|
12.2 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 07/09/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Greg S. Lea, SVP and Chief Financial Officer, is scheduled to present at the 7th Annual JMP Securities Heal...
|
|
EnteroMedics Added to Russell 3000(R) and Russell 2000(R) Indexes
Jun 25, 2012
|
13.6 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 06/25/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it has been added to the Russell 3000® and Russell 2000® Indexes. The company was included in both...
|
|
EnteroMedics Announces First Commercial Implants of the Maestro(R) Rechargeable System
Jun 5, 2012
|
61.0 KB |
|
| |
ST. PAUL, MN -- (MARKETWIRE) -- 06/05/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the completion of the first commercial implants of the Maestro® Rechargeable (RC) System, delivering VBLOC&#...
|
|
EnteroMedics to Present at the 9th Annual Craig-Hallum Institutional Investor Conference
May 29, 2012
|
11.8 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 05/29/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Mark B. Knudson, PhD President and Chief Executive Officer, is scheduled to present at the 9th Annual Craig...
|
|
EnteroMedics Reports First Quarter 2012 Financial Results
Apr 24, 2012
|
17.8 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 04/24/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced financial results for the three months ended March 31, 2012.
For the three months ended March 31,...
|
|
EnteroMedics to Host First Quarter 2012 Financial Results Conference Call and Provide Business Update
Apr 19, 2012
|
12.3 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 04/19/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it will host a conference call on Tuesday, April 24th, 2012 at 11:00 AM Eastern Time to discuss corporate u...
|
|
EnteroMedics Strengthens Financial Position With $20 Million Debt Agreement and $5.0 Million Equity Offering
Apr 17, 2012
|
14.1 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 04/17/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it has closed on a growth capital term loan for $20 million, amending its existing debt agreement with Sili...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter
